Entresto, developed by Novartis, is an innovative drug used for the treatment of chronic heart failure.

1、 Drug name

1. Common name: Sacubitril Valsartan Sodium Tablets

2. Product Name: Entresto

2、 Indications

1. Chronic heart failure: adults and children over 1 year old (must be used after receiving standard treatment).

2. High blood pressure: For adult use only (tablets 100mg/200mg).

3、 Specifications and characteristics

1. Ingot 100mg: Slightly yellow oval shaped film coated tablet, identification code L, size 13.1 × 5.2 × 3.7mm.

2. 200mg tablets: light red and white oval shaped film coated tablets, identification code NVRL11, size 15.1 × 6.0 × 5.4mm.

4、 Main components

Each tablet contains sacubitril valsartan sodium hydrate.

5、 Usage and dosage

1. Chronic heart failure:

(1) Adults: The initial dose is 50mg twice a day, gradually increasing to 200mg twice a day within 2-4 weeks if tolerated.

(2) Children: Calculate the starting dose based on body weight (0.8mg/kg twice daily) and gradually increase it to the target dose.

12. Hypertension:

(1) Adults: starting at 200mg once daily, maximum dose at 400mg once daily.

6、 Dose adjustment

1. Patients with renal dysfunction need to adjust their dosage carefully.

2. Elderly patients should start with low doses.

3. When intolerance occurs, appropriate reduction should be made.

7、 Medication precautions

1. Taking it with food can affect absorption, it is recommended to take it in a fixed way.

2. When missed, the dose should be skipped and should not be taken twice.

3. Vomiting after taking medication should be judged based on the time it takes to determine whether it needs to be taken again.

8、 Medication for special populations

1. Pregnant women: prohibited.

2. Breastfeeding period: It is recommended to stop breastfeeding.

3. Children: Available for ages 1 and above, but lacking data for newborns.

4. Elderly people: It is necessary to strengthen blood pressure and kidney function monitoring.

9、 Adverse reactions

1. Common: Hypotension (8.8%), Hyperkalemia (3.9%), Renal Dysfunction (2.4%).

2. Serious adverse reactions: angioedema (0.2%), renal failure (0.6%), shock (<0.1%).

10、 Contraindications

1. Individuals who are allergic to the ingredients of this product.

2. Those who are currently using ACEI drugs.

3. Individuals with a history of vascular edema.

4. Individuals with severe liver function impairment.

11、 Drug interactions

1. Prohibition of simultaneous use with ACEI drugs.

2. When used in combination with potassium sparing diuretics, blood potassium should be monitored.

3. Combined use with lithium agents may cause lithium poisoning.

12、 Storage method

Store at room temperature, with a shelf life of 3 years (tablets).

13、 Manufacturer

Novartis Pharmaceuticals and Otsuka Pharmaceuticals collaborate on production.

Entrestoinformation